19:25 , Oct 6, 2017 |  BC Week In Review  |  Company News

NIAID exercises option to develop MGD014 from MacroGenics

In early September, MacroGenics Inc. (NASDAQ:MGNX) said NIH's National Institute of Allergy and Infectious Disease (NIAID) exercised the first of two options under a September 2015 deal and will provide up to $10.8 million...
07:00 , Oct 22, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: CD3; HIV env

Infectious disease INDICATION: HIV / AIDS In vitro studies suggest a dual-affinity re-targeting (DART) antibody against CD3 and HIV env could help treat HIV infection. A DART consisting of two disulfide-linked polypeptide chains corresponding to the variable...